1. Volume 367, Issue 9518, Pages 1247-1255 (April 2006)
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial 
Prof Diane M Harper, MD, Prof Eduardo L Franco, PhD, Prof Cosette M Wheeler, PhD, Prof Anna-Barbara Moscicki, MD, Barbara Romanowski, MD, Cecilia M Roteli-Martins, MD, Prof David Jenkins, MD, Anne Schuind, MD, Sue Ann Costa Clemens, MD, Gary Dubin, MD 
The Lancet 
Volume 367, Issue 9518, Pages (April 2006)
DOI: /S (06)
Copyright © 2006 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial design
Follow-up time for each woman in each study phase varies dependent on when she completed her last study visit in the initial efficacy study and when she entered the extended follow-up phase.
The Lancet  , DOI: ( /S (06) )
Copyright © 2006 Elsevier Ltd Terms and Conditions

3. Figure 2
Geometric mean titres and seropositivity rates, according to HPV type and group in according-to-protocol analyses for immunogenicity
%=proportion of women seropositive. Sera from all vaccinees and a small number of samples from the placebo group of the initial study were retested.
The Lancet  , DOI: ( /S (06) )
Copyright © 2006 Elsevier Ltd Terms and Conditions